Raltegravir is effective for HIV-positive children, teens

01/8/2012 | United Press International

A national clinical trial of 96 HIV-positive children and adolescents showed that 53% of them achieved an undetectable amount of HIV in their blood after 24 weeks of treatment with raltegravir, which was recently approved by the FDA for use in children. The drug had no significant toxicities or interactions with other HIV drugs, the lead researcher said in a statement.

View Full Article in:

United Press International

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA